iX Biopharma (42C) will hold an extraordinary general meeting on Oct. 17 at 11:00 a.m. at its Singapore headquarters, according to a Tuesday filing on the Singapore Exchange.
The meeting will address three resolutions: extending the iX Employee Share Option Scheme (iX ESOS) and the iX Performance Share Plan (iX PSP) for an additional 10 years, until June 16, 2035, and allowing Eddy Lee Yip Hang, a controlling shareholder, to participate in the extended iX PSP.
Both schemes will limit total shares issued to 15% of the company's total issued shares, excluding treasury shares and subsidiary holdings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.